GlassScriptPhysician profile
Sherry M Meadows
NPI 1366496077
$7,529.10
in general payments reported to CMS, 2019-2025
49 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.24 · 2020: $12.00 · 2021: $56.45 · 2022: $26.53 · 2023: $2,226 · 2024: $2,480 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,391 · Education: $30.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,390.64 |
| Education | $30.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $778.08 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $708.08 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $642.54 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $494.56 | 2023-2025 | Imfinzi, Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $481.46 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Incyte Corporation | $310.47 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $300.99 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $279.34 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Myriad Genetic Laboratories, INC. | $276.26 | 2023-2024 | Bracanalysis Cdx, Myrisk |
| Abbvie INC. | $264.00 | 2023-2025 | |
| Daiichi Sankyo INC. | $186.30 | 2024-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $185.42 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $177.04 | 2023 | Padcev, Tukysa, Adcetris |
| Genentech USA, INC. | $163.46 | 2023-2025 | Venclexta, Tecentriq, Polivy |
| Celgene Corporation | $158.91 | 2023-2025 | Pomalyst, Reblozyl, Opdualag |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $158.67 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Pharmacosmos Therapeutics INC. | $134.43 | 2024-2025 | Monoferric |
| Eisai INC. | $134.03 | 2023-2025 | |
| Stemline Therapeutics INC. | $128.92 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $104.72 | 2023-2025 | Orgovyx |
| Blueprint Medicines Corporation | $103.69 | 2023-2024 | Ayvakit |
| Beone Medicines USA, INC. | $88.68 | 2025 | Brukinsa, Tevimbra |
| Sobi, INC | $86.89 | 2024-2025 | |
| Genzyme Corporation | $85.72 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.35 | 2023-2025 | |
| Astellas Pharma US INC | $76.52 | 2021-2025 | Xtandi |
| Fresenius Kabi USA, LLC | $72.20 | 2024-2025 | Stimufend |
| Beigene USA, INC. | $69.09 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $64.75 | 2021-2023 | Trodelvy |
| Exelixis INC. | $63.32 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $60.17 | 2022-2025 | Ojjaara |
| Kyowa Kirin, INC. | $58.54 | 2024 | Poteligeo |
| Amgen INC. | $58.13 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Caris Mpi, INC. | $57.48 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $57.04 | 2023-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.21 | 2023 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $50.19 | 2023-2024 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $40.92 | 2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $35.75 | 2024-2025 | |
| Kite Pharma, INC. | $32.21 | 2023-2025 | Yescarta |
| Tersera Therapeutics LLC | $31.12 | 2025 | Quzyttir |
| Pharmacyclics LLC, An Abbvie Company | $27.61 | 2023 | Imbruvica, Epkinly |
| Immunocore Limited | $20.01 | 2025 | Kimmtrak |
| Aveo Pharmaceuticals, INC. | $17.30 | 2025 | |
| Progenics Pharmaceuticals, INC. | $17.07 | 2024 | |
| Esperion Therapeutics, INC. | $16.11 | 2021 | |
| Puma Biotechnology, INC. | $14.47 | 2024 | |
| Karyopharm Therapeutics INC. | $14.16 | 2023 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $12.72 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.